Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class safety and efficacy profiles compared to all 3 major clinical-stage ADC technologies. Our ADC technology is clinical-stage and commercially validated through our deals with Shanghai Miracogen, ADC Therapeutics and Mersana Therapeutics. Synaffix offers a 'one-stop' ADC technology (including payloads) that enables the development of proprietary ADCs from any antibody and our patent portfolio provides granted protection of any resulting Products through at least 2035. Rather than developing a pipeline of drugs, the business model of Synaffix is technology out-licensing where we regularly engage in research collaborations with companies that are interested in developing highly competitive ADC Products using our proprietary technology.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Platform Technology / No Pipeline
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):